Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

53.05
-1.3000-2.39%
Post-market: 53.050.00000.00%19:58 EDT
Volume:890.94K
Turnover:47.30M
Market Cap:3.26B
PE:12.54
High:54.11
Open:53.67
Low:52.47
Close:54.35
Loading ...

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Benzinga
·
04 Mar

Protagonist Therapeutics Inc : JP Morgan Raises Target Price to $57 From $53

THOMSON REUTERS
·
04 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Melco Resorts, Chipotle, Allegro

Reuters
·
03 Mar

Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Phase 3 Success and Market Potential

TIPRANKS
·
03 Mar

Protagonist Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Results and Robust Financial Outlook

TIPRANKS
·
03 Mar

Stock Track | Protagonist Therapeutics Soars 12.13% as Blood Cancer Drug Rusfertide Succeeds in Phase 3 Trial, Meeting All Key Endpoints

Stock Track
·
03 Mar

Protagonist Therapeutics Shares up 9.8% as Blood Cancer Treatment Succeeds Late-Stage Study

THOMSON REUTERS
·
03 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, SolarEdge ,Protagonist

Reuters
·
03 Mar

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

MT Newswires Live
·
03 Mar

BUZZ-Protagonist climbs as blood cancer treatment succeeds late-stage study

Reuters
·
03 Mar

BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide

Reuters
·
03 Mar

Stock Track | Protagonist Therapeutics Soars 6.41% Pre-Market as Rusfertide Succeeds in Phase 3 PV Trial

Stock Track
·
03 Mar

Protagonist Therapeutics Inc - Rusfertide Generally Well Tolerated With No New Safety Findings

THOMSON REUTERS
·
03 Mar

Protagonist and Takeda Announce Positive Topline Results From Phase 3 Verify Study of Rusfertide in Patients With Polycythemia Vera

THOMSON REUTERS
·
03 Mar

Protagonist Therapeutics Inc - Study Meets Primary Endpoint With Higher Clinical Responders on Rusfertide

THOMSON REUTERS
·
03 Mar

Protagonist Therapeutics Inc - All Four Key Secondary Endpoints Met in Verify Study

THOMSON REUTERS
·
03 Mar